price
NASDAQ · CTMX
CytomX Therapeutics, Inc.
Healthcare · Biotechnology
$2.58
Down-$0.02 (-0.78%)
Updated Oct 7, 2026, 1:58 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 686.8M
- P/E ratio
- 23.88
- Dividend yield
- 0.00%
- 52-week range
- $2.48 – $8.21
- Volume
- 1.77M
- Avg. volume
- 3.54M
Price performance · CTMX
CTMX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CTMX closed at $2.58 after 20 trading sessions, down 29.32% for the selected period.
- Last close
- $2.58
- Period change
- -29.32%
- Period low
- $2.56
- Period high
- $3.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $2.55 | $2.67 | $2.48 | $2.58 | 1.77M |
| Oct 2, 2026 | $2.68 | $2.68 | $2.55 | $2.56 | 2.62M |
| Oct 1, 2026 | $2.71 | $2.775 | $2.62 | $2.63 | 2.7M |
| Sep 30, 2026 | $2.78 | $2.80 | $2.70 | $2.72 | 3.22M |
| Sep 29, 2026 | $2.70 | $2.825 | $2.65 | $2.75 | 4.46M |
| Sep 28, 2026 | $2.68 | $2.76 | $2.60 | $2.69 | 2.69M |
| Sep 25, 2026 | $2.74 | $2.78 | $2.66 | $2.70 | 3.03M |
| Sep 24, 2026 | $2.75 | $2.78 | $2.68 | $2.75 | 3.08M |
| Sep 23, 2026 | $2.90 | $2.91 | $2.67 | $2.78 | 4.96M |
| Sep 22, 2026 | $2.86 | $2.995 | $2.76 | $2.94 | 7.92M |
| Sep 21, 2026 | $2.80 | $2.83 | $2.7415 | $2.76 | 2.33M |
| Sep 18, 2026 | $2.83 | $2.86 | $2.72 | $2.76 | 9.6M |
| Sep 17, 2026 | $2.83 | $2.92 | $2.78 | $2.82 | 4.22M |
| Sep 16, 2026 | $2.72 | $2.865 | $2.6709 | $2.765 | 6.87M |
| Sep 15, 2026 | $3.20 | $3.205 | $2.665 | $2.69 | 7.51M |
| Sep 14, 2026 | $3.335 | $3.36 | $3.145 | $3.20 | 6.14M |
| Sep 11, 2026 | $3.38 | $3.406 | $3.23 | $3.29 | 2.25M |
| Sep 10, 2026 | $3.50 | $3.52 | $3.335 | $3.35 | 2.06M |
| Sep 9, 2026 | $3.66 | $3.66 | $3.495 | $3.54 | 2.05M |
| Sep 8, 2026 | $3.612 | $3.66 | $3.58 | $3.65 | 1.98M |
Latest CTMX news
The latest Smart Investors Daily articles mentioning CTMX.
Stock researchCompany · Financials
Company
Market Activity
Research & News
Loading stock research…